RYTM – Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc.RYTM
$105.01Name : Rhythm Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,007,953,408.00
EPSttm : -3.1
Rhythm Pharmaceuticals, Inc.
$105.01
1.90%$2.03Float Short %
8.95
Margin Of Safety %
Put/Call OI Ratio
0.63
EPS Next Q Diff
0.03
EPS Last/This Y
1.25
EPS This/Next Y
0.47
Price
104.97
Target Price
139
Analyst Recom
1.13
Performance Q
8
Relative Volume
0.53
Beta
2.01
Ticker: RYTM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-08 | RYTM | 105.15 | 0.58 | 2.06 | 8235 |
| 2025-12-09 | RYTM | 100.71 | 0.56 | 2.00 | 8489 |
| 2025-12-10 | RYTM | 107.77 | 0.57 | 0.69 | 8505 |
| 2025-12-11 | RYTM | 117 | 0.56 | 0.07 | 8508 |
| 2025-12-12 | RYTM | 113.51 | 0.48 | 0.04 | 9576 |
| 2025-12-15 | RYTM | 112.54 | 0.44 | 0.00 | 10101 |
| 2025-12-16 | RYTM | 112.45 | 0.42 | 0.00 | 10430 |
| 2025-12-17 | RYTM | 111.85 | 0.44 | 0.04 | 10075 |
| 2025-12-18 | RYTM | 111.73 | 0.46 | 0.11 | 9847 |
| 2025-12-19 | RYTM | 112.05 | 0.47 | 0.12 | 9733 |
| 2025-12-22 | RYTM | 112.97 | 0.53 | 0.39 | 8399 |
| 2025-12-23 | RYTM | 112.36 | 0.54 | 0.00 | 8418 |
| 2025-12-26 | RYTM | 110.12 | 0.53 | 0.00 | 8428 |
| 2025-12-29 | RYTM | 112.58 | 0.59 | 0.00 | 7935 |
| 2025-12-30 | RYTM | 106.86 | 0.59 | 0.02 | 7948 |
| 2025-12-31 | RYTM | 107.15 | 0.59 | 0.03 | 7947 |
| 2026-01-02 | RYTM | 105.08 | 0.63 | 0.18 | 7718 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-08 | RYTM | 105.18 | -4.6 | - | -3.05 |
| 2025-12-09 | RYTM | 100.71 | -4.6 | - | -3.05 |
| 2025-12-10 | RYTM | 104.79 | -4.6 | - | -3.05 |
| 2025-12-11 | RYTM | 117.56 | -4.6 | - | -3.05 |
| 2025-12-12 | RYTM | 113.53 | -4.6 | - | -3.05 |
| 2025-12-15 | RYTM | 112.52 | -4.6 | - | -3.05 |
| 2025-12-16 | RYTM | 112.52 | -4.6 | - | -3.05 |
| 2025-12-17 | RYTM | 111.82 | -4.6 | - | -3.05 |
| 2025-12-18 | RYTM | 111.67 | -8.5 | - | -3.08 |
| 2025-12-19 | RYTM | 112.10 | -8.5 | - | -3.08 |
| 2025-12-22 | RYTM | 113.09 | -8.5 | - | -3.08 |
| 2025-12-23 | RYTM | 111.81 | -8.5 | - | -3.08 |
| 2025-12-26 | RYTM | 110.06 | -9.0 | - | -3.09 |
| 2025-12-29 | RYTM | 112.48 | -9.0 | - | -3.09 |
| 2025-12-30 | RYTM | 106.89 | -9.0 | - | -3.09 |
| 2025-12-31 | RYTM | 107.02 | -9.0 | - | -3.09 |
| 2026-01-02 | RYTM | 104.97 | -9.0 | - | -3.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-08 | RYTM | -4.12 | 7.30 | 8.83 |
| 2025-12-09 | RYTM | -4.12 | 7.30 | 8.83 |
| 2025-12-10 | RYTM | -4.12 | 7.30 | 8.85 |
| 2025-12-11 | RYTM | -3.97 | 7.30 | 8.85 |
| 2025-12-12 | RYTM | -3.97 | 7.30 | 8.85 |
| 2025-12-15 | RYTM | -4.00 | 7.30 | 8.85 |
| 2025-12-16 | RYTM | -4.00 | 7.30 | 8.85 |
| 2025-12-17 | RYTM | -4.00 | 7.30 | 8.85 |
| 2025-12-18 | RYTM | -4.00 | 7.30 | 8.85 |
| 2025-12-19 | RYTM | -4.00 | 7.30 | 8.85 |
| 2025-12-22 | RYTM | -4.00 | 7.31 | 8.85 |
| 2025-12-23 | RYTM | -4.00 | 7.31 | 8.85 |
| 2025-12-26 | RYTM | -4.00 | 7.31 | 8.95 |
| 2025-12-29 | RYTM | -4.00 | 7.31 | 8.95 |
| 2025-12-30 | RYTM | -4.00 | 7.31 | 8.95 |
| 2025-12-31 | RYTM | -4.00 | 7.31 | 8.95 |
| 2026-01-02 | RYTM | -4.00 | 7.31 | 8.95 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.82
Avg. EPS Est. Current Quarter
-0.79
Avg. EPS Est. Next Quarter
-0.79
Insider Transactions
-4
Institutional Transactions
7.31
Beta
2.01
Average Sales Estimate Current Quarter
55
Average Sales Estimate Next Quarter
58
Fair Value
Quality Score
45
Growth Score
37
Sentiment Score
20
Actual DrawDown %
14.1
Max Drawdown 5-Year %
-92.1
Target Price
139
P/E
Forward P/E
PEG
P/S
40.2
P/B
47.05
P/Free Cash Flow
EPS
-3.1
Average EPS Est. Cur. Y
-3.09
EPS Next Y. (Est.)
-2.62
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-113.41
Relative Volume
0.53
Return on Equity vs Sector %
-94.1
Return on Equity vs Industry %
-78.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
Rhythm Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 283
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today
news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance
stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market
stock prices RYTM premarket after hours
ticker RYTM fair value insiders trading